RESUMEN
The aim of this study was to show the effect of raloxifene on the lowering of lipid parameters in patients with osteoporosis. New investigations introduced selective estrogen receptor modulators (SERMs), such as raloxifene, as a potent drug in the lowering of lipid parameters. Raloxifene is known as a substance that works well in preventing and treating osteoporosis. We investigated the effect of raloxifene on the lowering of lipid parameters (cholesterol and triglycerides) in 94 women who took 60 mg/day of raloxifene for the treatment of osteoporosis. We performed three measurements of cholesterol and triglycerides, at the beginning of the study and at 3 and 12 months. Bone mineral density (BMD) was measured at the begining and at 12 months; spine BMD increased 2.7%. The mean value of cholesterol was 6.6961 mmol/l at the beginning, 6.060 mmol/l at 3 months and 5.826 mmol/l at 12 months. The difference between mean values was statistically significant at p < 0.01. Mean values of triglycerides were 2.153 mmol/l at the beginning, 1.970 mmol/l at 3 months and 1.680 mmol/l at 12 months. The difference between mean values at 3 months was statistically significant at p < 0.05 and at 12 months at p < 0.01. We concluded that raloxifene had significant effects on lowering cholesterol and triglycerides in postmenopausal women and that raloxifene is the best choice in the treatment of osteoporosis and moderate lipid disorders.
Asunto(s)
Densidad Ósea/efectos de los fármacos , Colesterol/sangre , Osteoporosis/tratamiento farmacológico , Clorhidrato de Raloxifeno/uso terapéutico , Moduladores Selectivos de los Receptores de Estrógeno/uso terapéutico , Triglicéridos/sangre , Anciano , Femenino , Humanos , Persona de Mediana EdadRESUMEN
A group of 101 patients with diffuse hyperthyroid goiter has been studied. Sixty-seven patients showed significantly increased level of antibodies to the TSH receptor (TBIAb), 48 patients had positive microsomal antibodies (MAb) and 41 patients had infiltrative ophthalmopathy. On the basis of cytologic analysis of the whole group, the patients were divided into two groups. Group A (n = 51, autonomous form?) was characterized by follicular cell proliferation, while group B (n = 50, autoimmune form?) was characterized by lymphocyte infiltration or follicular cell proliferation with lymphocyte traces. Cytologic findings were correlated with autoimmunity markers (TBIAb, MAb, infiltrative ophthalmopathy); multiple correlation factor was 0.17. In conclusion, cytologic classification into autonomous and autoimmune hyperthyroidism form, except by microsomal antibodies, is not followed by other autoimmunity markers.